CRISPR and Cancer

Chinese researchers have developed a thermosensitive, polyamine-modified hydrogel that significantly improves the co-delivery of CRISPR/Cas9 gene...

SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in...

Using CRISPR-Cas9 screens, researchers in the United States, Belgium and China have identified NR2F2 as a key driver of endocrine resistance in breast...

New clinical data from Allogene Therapeutics' Phase 1 TRAVERSE trial reveals durable responses in patients with heavily pre-treated advanced renal...

Researchers in China report that orally-administered CRISPR-Cas9-loaded nanoparticles, designed to target the mitochondrial chaperone TRAP1, overcome...

A new review outlines genetic engineering strategies, including CRISPR, to enhance the therapeutic potential of innate immune cells in cancer...

A study published today in Nature Communications demonstrates a CRISPR-Cas9 strategy for engineering haematopoietic stem and progenitor cells (HSPCs)...

Researchers have identified ARL11 as a critical factor in resistance to PARP inhibitor therapy through a genome-wide CRISPR activation screen,...